We are live on ! Find out more
LBPS

4D Pharma PLC
LBPS

Delisted

LBPS was delisted on the 24th of June, 2022.

Back to rankings

8 hedge funds and large institutions have $430K invested in 4D Pharma PLC in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% less funds holding

Funds holding: 10 → 8 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

79% less capital invested

Capital invested by funds: $2.03M → $430K (-$1.6M)

Holders
8
Holders Change
-2
Holders Change %
-20%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$5.57K
2
Osaic Holdings
Osaic Holdings
Arizona
+$1.78K

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$483K
2
Morgan Stanley
Morgan Stanley
New York
-$133K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$57K
4
TRCT
Tower Research Capital (TRC)
New York
-$13.1K
5
Citadel Advisors
Citadel Advisors
Florida
-$11.5K

LBPS Hedge Fund Activity: Q2 2022 in Review

8 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q2 2022, worth a combined $430K — down 79% from $2.03M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LBPS and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Credit Suisse, opening a new position worth an estimated $5.57K. The largest seller was Kepos Capital, exiting entirely with an estimated $483K sold.

  • 8 institutional investors held 4D Pharma PLC (LBPS) as of Q2 2022, down from 10 in Q1 2022.
  • Funds reported $430K of 4D Pharma PLC stock for Q2 2022, down 79% quarter-over-quarter.
  • 1 fund opened new 4D Pharma PLC positions in Q2 2022 and 3 closed out, a net change of -2 holders.
  • The largest 4D Pharma PLC buyer in Q2 2022 was Credit Suisse, an estimated $5.57K added.
  • The largest 4D Pharma PLC seller in Q2 2022 was Kepos Capital, an estimated $483K sold.

Based on aggregated 13F filings for Q2 2022.